AA
ITOS

AlphaCentric Advisors’s iTeos Therapeutics ITOS Stock Holding History

AlphaCentric Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-63,000
Closed -$834K – 248
2023
Q2 		$834K Hold
63,000
– – 0.46% 77
2023
Q1 		$857K Buy
+63,000
New +$1.13M 0.59% 62
2021
Q4 		$698K Buy
+15,000
New +$499K 0.2% 49

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AlphaCentric Advisors's ITOS Position: Q3 2023 in Review

AlphaCentric Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2023, closing a stake of 63,000 shares — an estimated $834K sold.

AlphaCentric Advisors first reported a position in ITOS in Q4 2021 and held it in 3 quarters. The position peaked at $857K in Q1 2023. 144 funds tracked by Wall St. Rank hold ITOS as of Q3 2023.

  • AlphaCentric Advisors reported no remaining iTeos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • AlphaCentric Advisors sold 63,000 iTeos Therapeutics shares in Q3 2023, an estimated $834K.
  • AlphaCentric Advisors first reported a position in iTeos Therapeutics in Q4 2021 and held it in 3 quarters.
  • AlphaCentric Advisors's iTeos Therapeutics position peaked at $857K in Q1 2023.
  • 144 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2023.

Based on AlphaCentric Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.